Latest News & Features
Biotechnology
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally. 1 March 2021
article
Since the formalisation of the new BPCIA framework in 2014, we have seen a wave of patent infringement suits filed leading to a trend of innovator-versus-biosimilar disputes. What are the trends shown by these early suits, and what legal and strategic questions do they raise? 25 February 2021
Big Pharma
Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents. 25 February 2021
Biotechnology
Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes. 25 February 2021
Americas
Medical device maker Nevro has hit competitor Boston Scientific with a lawsuit for allegedly infringing patents that cover a spinal cord stimulation technology. 25 February 2021
Americas
A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug. 25 February 2021
Big Pharma
Innovation by medical and pharma sectors has increased over the past year in the wake of the pandemic, a new report by IP services company Clarivate has confirmed. 23 February 2021
Big Pharma
Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes. 23 February 2021
Big Pharma
AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau. 23 February 2021
Americas
The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer. 22 February 2021